Helius Medical Technologies, Inc. Announces Claim Authorization by CignaHealth, for its Portable Neuromodulation Stimulator (PoNS®) Device

Core Insights - CignaHealth has authorized claims for the PoNS Device at an out-of-network adjusted negotiated list price of $19,161, marking it as the fifth major payer to do so, following Anthem Multiplan's authorization at a similar price of $19,160 [1][2] - The authorization from five major commercial healthcare payers is expected to enhance access for multiple sclerosis (MS) patients to the PoNS device, reinforcing its value and supporting efforts for broader reimbursement from CMS [2] Group 1: PoNS Device Overview - The Portable Neuromodulation Stimulator (PoNS) is a non-implantable therapy that delivers neurostimulation through a mouthpiece, primarily used at home alongside physical rehabilitation exercises to improve balance and gait [3] - The PoNS device is indicated for short-term treatment of gait deficits due to mild-to-moderate symptoms from MS, and is prescribed for patients aged 22 and over [3] Group 2: Effectiveness and Authorization - PoNS has demonstrated effectiveness in treating gait and balance issues, significantly reducing the risk of falls in stroke patients in Canada, where it is authorized for three indications related to stroke and traumatic brain injury [4] - The device is also authorized for sale in Australia for short-term use by healthcare professionals as an adjunct to therapeutic exercise programs [4] Group 3: Company Background - Helius Medical Technologies is a leading neurotech company focused on neurologic deficits, utilizing an orally applied technology platform to enhance the brain's compensatory mechanisms and promote neuroplasticity [5] - The company's first commercial product is the Portable Neuromodulation Stimulator, aimed at improving the lives of individuals with neurologic diseases [5]